GlassScriptPhysician profile
Joseph C Jones
NPI 1295937936
$2,862.74
in general payments reported to CMS, 2019-2025
32 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $130 · 2021: $48.24 · 2022: $104 · 2023: $584 · 2024: $793 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $406.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $336.78 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $295.92 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $271.01 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $157.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.71 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Phathom Pharmaceuticals, INC. | $100.01 | 2024-2025 | Voquezna |
| Dexcom, INC. | $93.89 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $91.56 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $88.47 | 2024-2025 | |
| Corcept Therapeutics | $78.69 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $70.69 | 2023-2025 | Rexulti |
| Abbvie INC. | $70.13 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.16 | 2019-2024 | Relistor |
| Daiichi Sankyo INC. | $63.34 | 2019-2023 | Injectafer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $61.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.50 | 2019-2022 | |
| Astellas Pharma US INC | $49.52 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.70 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $45.92 | 2019 | |
| Abiomed | $36.76 | 2024-2025 | Impella |
| Abbott Laboratories | $31.02 | 2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $30.82 | 2024 | Keveyis |
| Idorsia Pharmaceuticals US INC | $29.06 | 2023 | Quviviq |
| Mylan Specialty L.P. | $22.35 | 2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $20.79 | 2025 | Libtayo |
| Verona Pharma, INC. | $19.21 | 2025 | Ohtuvayre |
| Lundbeck LLC | $17.89 | 2024 | Rexulti |
| Viatris Specialty LLC | $16.34 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $15.14 | 2023 | Terlivaz |
| Allergan, INC. | $14.45 | 2019 | |
| Inogen, INC. | $14.06 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.